Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 13 | 2018 | 84 | 2.710 |
Why?
|
| Alcoholism | 18 | 2025 | 305 | 2.110 |
Why?
|
| Substance-Related Disorders | 15 | 2024 | 830 | 1.860 |
Why?
|
| Mental Disorders | 12 | 2019 | 392 | 1.340 |
Why?
|
| Alcohol Drinking | 7 | 2025 | 609 | 1.210 |
Why?
|
| Patient-Centered Care | 4 | 2010 | 75 | 0.960 |
Why?
|
| Substance Abuse Treatment Centers | 3 | 2024 | 22 | 0.900 |
Why?
|
| Alcohol-Related Disorders | 4 | 2016 | 63 | 0.880 |
Why?
|
| Nerve Net | 1 | 2025 | 101 | 0.860 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 14 | 2017 | 44 | 0.820 |
Why?
|
| Psychotherapy | 8 | 2017 | 59 | 0.720 |
Why?
|
| Comorbidity | 19 | 2019 | 737 | 0.680 |
Why?
|
| Cocaine-Related Disorders | 5 | 2009 | 102 | 0.590 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2017 | 1 | 0.540 |
Why?
|
| Valproic Acid | 4 | 2006 | 21 | 0.540 |
Why?
|
| Central Nervous System Agents | 1 | 2017 | 8 | 0.520 |
Why?
|
| Yoga | 1 | 2017 | 33 | 0.520 |
Why?
|
| Brain | 1 | 2025 | 1472 | 0.520 |
Why?
|
| Mianserin | 1 | 2016 | 1 | 0.500 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 65 | 0.480 |
Why?
|
| Caffeine | 1 | 2015 | 28 | 0.460 |
Why?
|
| Humans | 47 | 2025 | 43102 | 0.450 |
Why?
|
| Integrative Medicine | 2 | 2010 | 8 | 0.420 |
Why?
|
| Cannabis | 1 | 2015 | 90 | 0.410 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 252 | 0.390 |
Why?
|
| Ethanol | 1 | 2015 | 224 | 0.390 |
Why?
|
| Cocaine | 1 | 2015 | 251 | 0.380 |
Why?
|
| Antimanic Agents | 3 | 2008 | 9 | 0.380 |
Why?
|
| Nicotine | 1 | 2015 | 302 | 0.370 |
Why?
|
| Treatment Outcome | 12 | 2018 | 1604 | 0.360 |
Why?
|
| Personality | 1 | 2011 | 55 | 0.340 |
Why?
|
| Diagnosis | 1 | 2010 | 10 | 0.340 |
Why?
|
| HIV Infections | 5 | 2005 | 2586 | 0.340 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 706 | 0.330 |
Why?
|
| Congresses as Topic | 1 | 2010 | 50 | 0.330 |
Why?
|
| Concept Formation | 1 | 2010 | 25 | 0.330 |
Why?
|
| Depression | 2 | 2016 | 863 | 0.330 |
Why?
|
| Anxiety | 1 | 2017 | 874 | 0.310 |
Why?
|
| Adult | 19 | 2025 | 13872 | 0.300 |
Why?
|
| Motivation | 2 | 2011 | 513 | 0.290 |
Why?
|
| Double-Blind Method | 6 | 2018 | 317 | 0.290 |
Why?
|
| Anticonvulsants | 2 | 2008 | 40 | 0.290 |
Why?
|
| Male | 26 | 2025 | 23409 | 0.270 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2009 | 282 | 0.270 |
Why?
|
| Patient Compliance | 6 | 2009 | 233 | 0.270 |
Why?
|
| Female | 26 | 2025 | 24698 | 0.270 |
Why?
|
| International Cooperation | 1 | 2007 | 52 | 0.260 |
Why?
|
| Fluoxetine | 4 | 2011 | 15 | 0.260 |
Why?
|
| Antipsychotic Agents | 2 | 2006 | 80 | 0.250 |
Why?
|
| Anti-HIV Agents | 3 | 2005 | 486 | 0.240 |
Why?
|
| Continuity of Patient Care | 2 | 2003 | 120 | 0.230 |
Why?
|
| Health Status | 4 | 2010 | 442 | 0.230 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2005 | 40 | 0.230 |
Why?
|
| Combined Modality Therapy | 9 | 2018 | 173 | 0.220 |
Why?
|
| Marijuana Abuse | 2 | 2005 | 100 | 0.220 |
Why?
|
| Adolescent | 12 | 2011 | 6081 | 0.200 |
Why?
|
| Psychotic Disorders | 3 | 2009 | 71 | 0.190 |
Why?
|
| Middle Aged | 14 | 2018 | 12222 | 0.180 |
Why?
|
| Language | 1 | 2024 | 185 | 0.180 |
Why?
|
| Medicaid | 1 | 2024 | 143 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 587 | 0.180 |
Why?
|
| Prevalence | 5 | 2006 | 1612 | 0.170 |
Why?
|
| Psychiatry | 2 | 2011 | 36 | 0.160 |
Why?
|
| Young Adult | 3 | 2025 | 5080 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2016 | 760 | 0.160 |
Why?
|
| Carbamates | 1 | 2018 | 13 | 0.150 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2018 | 81 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 74 | 0.140 |
Why?
|
| United States | 4 | 2024 | 5205 | 0.130 |
Why?
|
| Affect | 2 | 2011 | 180 | 0.130 |
Why?
|
| Residential Facilities | 1 | 2016 | 8 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 375 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2017 | 259 | 0.120 |
Why?
|
| Community Health Centers | 1 | 2016 | 57 | 0.120 |
Why?
|
| Polysomnography | 1 | 2015 | 43 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2011 | 1067 | 0.110 |
Why?
|
| Housing | 2 | 2005 | 74 | 0.110 |
Why?
|
| Education | 2 | 2011 | 60 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2003 | 150 | 0.100 |
Why?
|
| Aged | 6 | 2008 | 8214 | 0.090 |
Why?
|
| Humanism | 1 | 2010 | 3 | 0.080 |
Why?
|
| Tranquilizing Agents | 1 | 2010 | 1 | 0.080 |
Why?
|
| Mood Disorders | 1 | 2010 | 54 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 206 | 0.080 |
Why?
|
| Research | 1 | 2011 | 181 | 0.070 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 50 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2006 | 719 | 0.070 |
Why?
|
| Psychotropic Drugs | 2 | 2009 | 18 | 0.070 |
Why?
|
| Cyclothymic Disorder | 1 | 2008 | 1 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2009 | 1234 | 0.070 |
Why?
|
| Counseling | 2 | 2006 | 138 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 310 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2009 | 180 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2006 | 9 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Veterans | 1 | 2008 | 210 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 41 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2006 | 161 | 0.050 |
Why?
|
| Conduct Disorder | 1 | 2005 | 54 | 0.050 |
Why?
|
| Naltrexone | 1 | 2004 | 34 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2005 | 93 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2004 | 12 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 1 | 2004 | 16 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 98 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2004 | 63 | 0.050 |
Why?
|
| Attitude to Health | 2 | 2003 | 338 | 0.050 |
Why?
|
| Psychopharmacology | 1 | 2003 | 2 | 0.050 |
Why?
|
| Comprehensive Health Care | 1 | 2003 | 11 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 76 | 0.050 |
Why?
|
| Methadone | 1 | 2003 | 24 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 54 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Behavioral Symptoms | 1 | 2002 | 7 | 0.050 |
Why?
|
| Behavior, Addictive | 1 | 2003 | 37 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2003 | 60 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2003 | 140 | 0.050 |
Why?
|
| Personality Assessment | 1 | 2002 | 45 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 234 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2004 | 187 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 120 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2004 | 112 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 236 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 229 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 138 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2003 | 178 | 0.050 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 174 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 322 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 235 | 0.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 298 | 0.040 |
Why?
|
| Health Behavior | 1 | 2005 | 575 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2003 | 269 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2002 | 359 | 0.040 |
Why?
|
| Logistic Models | 1 | 2004 | 1009 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2003 | 281 | 0.040 |
Why?
|
| Sick Role | 2 | 2010 | 9 | 0.040 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2018 | 6 | 0.040 |
Why?
|
| Recurrence | 3 | 2004 | 152 | 0.040 |
Why?
|
| Prodrugs | 1 | 2018 | 31 | 0.040 |
Why?
|
| Child | 1 | 2005 | 3443 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2018 | 180 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2010 | 1063 | 0.030 |
Why?
|
| Sexual Behavior | 2 | 2016 | 638 | 0.030 |
Why?
|
| Prognosis | 2 | 2009 | 861 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 298 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2009 | 1600 | 0.020 |
Why?
|
| Training Support | 1 | 2011 | 8 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2011 | 11 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 35 | 0.020 |
Why?
|
| MEDLINE | 1 | 2010 | 9 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 136 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 48 | 0.020 |
Why?
|
| Health Services Research | 1 | 2010 | 161 | 0.020 |
Why?
|
| Patient Participation | 1 | 2010 | 94 | 0.020 |
Why?
|
| Urinalysis | 1 | 2009 | 34 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 98 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 368 | 0.020 |
Why?
|
| Risk Factors | 2 | 2009 | 3994 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2005 | 749 | 0.020 |
Why?
|
| Awareness | 1 | 2008 | 73 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 3156 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 16 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 56 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 116 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2005 | 34 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 2005 | 76 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 27 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 48 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2005 | 63 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2004 | 10 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 74 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2005 | 108 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2003 | 23 | 0.010 |
Why?
|
| Antisocial Personality Disorder | 1 | 2003 | 20 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2004 | 139 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2003 | 32 | 0.010 |
Why?
|
| Low Back Pain | 1 | 2004 | 101 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 575 | 0.010 |
Why?
|
| Safe Sex | 1 | 2003 | 78 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 287 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 452 | 0.010 |
Why?
|
| Suicide | 1 | 2004 | 140 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 167 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 490 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1124 | 0.010 |
Why?
|
| Quality of Life | 1 | 2005 | 616 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1028 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2004 | 2544 | 0.010 |
Why?
|
| Neoplasms | 1 | 2005 | 1377 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 16992 | 0.000 |
Why?
|